Business
Tactile Systems Technology, Inc. Announces Appointment of Daniel L. Reuvers as President and Chief Executive Officer
MINNEAPOLIS, May 21, 2020 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on
About this update from Tactile Systems Technology, Inc.
[{"type":"text","content":"MINNEAPOLIS, May 21, 2020 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today announced that Daniel L. Reuvers has been appointed President and Chief Executive Officer, effective June 8, 2020, to succeed Gerald R. Mattys who is retiring, as previously disclosed. Mr. Reuvers will also join the Board of Directors, effective June 8, 2020, filling a seat created by Mr. Mattys’ retirement from the Board, effective that same day. Mr. Mattys will serve as a consultant to the Company until June 2021 to ensure a seamless transition.\n “After a comprehensive search process which yielded several highly qualified candidates, I am very pleased to announce that the Board of Directors has voted unanimously to appoint Dan Reuvers to the role of President and Chief Executive Officer,” said Peter H. Soderberg, Chairman of the Company’s Board of Directors. “With more than 30 years of experience in the medical device industry, a proven track record of leading global medical device businesses and company leadership experience with our direct prescriber-to-payer-to-patient business model, we believe Dan is the ideal executive to lead Tactile Medical during its next stage of growth and value creation.” “On behalf of the Board, I would like to express to Jerry our deep gratitude for his 15 years of service to our Company. He has taken us from infancy to a high growth, high performing company that is making a tremendous difference every day in the lives of tens of thousands of patients suffering from chronic swelling conditions such as lymphedema and chronic venous insufficiency. His legacy will be substantial, and we wish him continued personal growth in his retirement.” Mr. Soderberg continued: “Dan comes to us after 12 years with Integra LifeSciences, where he currently serves as EVP and President of Codman Specialty Surgical, Integra’s largest business. He led Integra’s acquisition and integration of Johnson & Johnson’s Codman Neurosurgery business, combining it with Integra’s neurosurgery business to create a $1 billion leader in neurosurgery. Previously, as Corporate Vice President and President of International from 2013 to 2016, Dan was responsible for Integra’s $200 million business outside...